Extended Data Fig. 3: Deleterious ctDNA SNVs enriched at progression in non-responders.
Deleterious ctDNA SNVs enriched 5-fold in progression samples from non-responders (change of SLD > -20%) compared to baseline. Deleterious variants identified in tumor WES are also shown. N = 9 patients.
